Continuous Glucose Monitoring in Type 2 Diabetes and Beyond: A Review

The authors aim to evaluate the efficacy and appropriateness of continuous glucose monitoring (CGM) for individuals with type 2 diabetes and beyond, given its initial focus on type 1 diabetes. They found that while CGM can lead to a modest reduction in hemoglobin A1c for some patients with type 2 diabetes, evidence for its use in those not on glucose-lowering therapy or in populations like prediabetics remains limited. The authors advocate for a targeted approach to CGM deployment, ensuring it aligns with patient needs and clinical contexts to maximize benefits and prevent overuse.